{"id":"decimemide","rwe":[],"tags":[{"label":"Small Molecule","category":"modality"},{"label":"Active","category":"status"}],"phase":"phase_2","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":"denegyt","offLabel":[],"synonyms":["decimemide","denegyt"],"timeline":[],"approvals":[],"brandName":"Denegyt","ecosystem":[],"mechanism":{"modality":"Small Molecule","explanation":"Imagine your body's cells have a specific lock that needs to be turned to work properly. Denegyt is a key that fits into this lock, allowing the cell to function correctly and potentially treating a disease or condition. This is a simplified explanation of how Denegyt works at a molecular level.","oneSentence":"Denegyt works by modulating a specific molecular target to produce a therapeutic effect.","technicalDetail":"Denegyt is a small molecule that binds to a specific protein target, altering its activity and leading to a downstream effect on cellular function. The exact mechanism of action is unknown, but it is thought to involve modulation of ion channels or other signaling pathways."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/3127","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=DECIMEMIDE","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T10:26:12.762571","biosimilars":[],"competitors":[],"genericName":"decimemide","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[],"trialDetails":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"UNII":"GAF9GJ18J5","CHEBI":"CHEBI:135434","INN_ID":"2969","UMLSCUI":"C2699569","ChEMBL_ID":"CHEMBL91688","PUBCHEM_CID":"26929"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":0,"therapeuticAreas":["Other"],"biosimilarFilings":[],"recentPublications":[],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Denegyt (Decimemide) is a small molecule modality with unknown target and drug class. Its commercial status is unclear, and it has not been approved by the FDA for any indications. As a result, there is limited information available on its pharmacokinetic properties, such as half-life and bioavailability. Further research is needed to determine its potential therapeutic applications and safety profile. The lack of approved indications and patent status makes it challenging to assess its commercial viability.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":false,"score":1}}